multiple myeloma

Robust multiple myeloma treatment program holds promiseThe Medical College of Wisconsin’s multiple myeloma program is robust and growing.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
FDA approves a new immune-stimulating drug to treat multiple myelomaFDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
First-of-its kind myeloma drug approvedThe FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.
ASCO set to compare value of cancer drugsThe American Society of Clinical Oncology is asking for comments on its ASCO Value Framework, which compares the value of new cancer therapies with established treatments.
What's the verdict: A case of changing medical recordsA step-by-step examination of a malpractice suit in which a patient claims to be suffering from multiple myeloma and asked for opioids. When it is revealed the patient lied about the need for opioids, the physician assistant changed the medical records before a lawsuit.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations
FDA approves multiple myeloma drugFDA approved Farydak (panobinostat) for the treatment of patients with multiple myeloma, which is attributed to 10,710 deaths in the U.S. annually.